Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MEMEDSthis companyDataMEDS AI, Inc.	$0.96	-0.28×	-2.28×	1.22×	-0.57×	-913.2%	-41.3%	-347.9%	-433.9%	813.6%	-659.0%	-38.3%	-1.99×	-0.26×	-17.73×	0.09×	0.0%	1	-12.67	2	C
ALGSAligos Therapeutics, Inc.	$4.54	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
BDSXBiodesix, Inc.	$8.23	-1.46×	-20.83×	0.58×	-4.79×	-1313.6%	81.1%	-31.4%	-39.8%	1430.6%	-38.9%	-46.1%	-29.56×	-2.45×	-3.6×	1.86×	0.0%	4	-5.55	1	D+
BEATHeartBeam, Inc.	$0.40	-3.87×	31.08×	0×	-3.65×	-74.8%	0.0%	0.0%	0.0%	-807.3%	-812.1%	-18.0%	0×	0.21×	0×	1.45×	0.0%	2	-11.41	1	C-
INMBINmune Bio, Inc.	$1.14	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
OKUROnKure Therapeutics, Inc.	$2.78	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
Peer median	—	-1.46×	1.72×	0.58×	-3.45×	-74.8%	57.5%	-31.4%	-39.8%	-105.9%	-123.9%	-57.0%	0.01×	0.52×	0×	3.55×	0.0%	2	-9.17	2	—